Skip to main content
Subscribe
Register
Sign in
Membership
Events
Knowledge Center
About
Subscribe
Register
Sign in
Premium
Alternative Insight and Premium Journalism
Latest Articles
Premium
Life Sciences Hedge Funds Make a Stunning Recovery
Stephen Taub
January 11, 2024
Premium
Viking Stands Apart From Other Tiger Cubs
Stephen Taub
January 10, 2024
Premium
Jamie Sterne’s Skye Global Soars Again
Stephen Taub
January 9, 2024
Premium
How Dan Loeb’s Hedge Fund Turned It Around in the Fourth Quarter
Stephen Taub
January 8, 2024
Premium
AQR Tops Multistrategy Funds in 2023
Stephen Taub
January 5, 2024
Premium
Tepper’s Two-Year Feat
Stephen Taub
January 4, 2024
Premium
Hedge Fund Faves Beat the Market in the Fourth Quarter
Stephen Taub
January 3, 2024
Premium
Greenlight Finishes the Year on a Losing Note
Stephen Taub
January 2, 2024
Premium
Hedge Funds Seek Health Care Deals
Stephen Taub
December 21, 2023
Premium
Why Seligman Thinks Tesla Is Still an Attractive Short
Stephen Taub
December 20, 2023
Premium
Another Quiet Year for VC Deals
Stephen Taub
December 19, 2023
Premium
Electron Suffers a Setback
Stephen Taub
December 18, 2023
Premium
Why D1 Capital Partners Is Lagging the Tiger Crowd
Stephen Taub
December 14, 2023
Premium
Tiger Funds Add to Gains
Stephen Taub
December 13, 2023
Premium
Life Sciences Funds Generate Healthy November Gains
Stephen Taub
December 12, 2023
Premium
Haidar Is Down 50 Percent
Stephen Taub
December 11, 2023
Premium
How Third Point Fared After Increasing Bets on Stocks
Stephen Taub
December 7, 2023
Premium
Prominent Hedge Funds Stand to Benefit From Biopharma’s Change of Plans
Stephen Taub
December 6, 2023
More Articles